Galmed Pharmaceuticals Stock Analysis

Galmed Stock Analysis Notes

The company has price-to-book (P/B) ratio of 0.18. Some equities with similar Price to Book (P/B) outperform the market in the long run. Galmed Pharmaceuticals recorded earning per share (EPS) of 69.72. The entity had not issued any dividends in recent years. The firm had 1:12 split on the 30th of August 2024. Galmed Pharmaceuticals Ltd., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of liver diseases. Galmed Pharmaceuticals Ltd. was founded in 2000 and is headquartered in Tel Aviv, Israel. Galmed Pharmaceutica operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 19 people. To learn more about Galmed Pharmaceuticals call Allen Baharaff at 972 3 693 8448 or check out https://www.galmedpharma.com.

Galmed Pharmaceuticals Investment Alerts

Galmed Pharmaceuticals Upcoming and Recent Events

Galmed Largest EPS Surprises

View All Earnings Estimates

Galmed Pharmaceuticals Environmental, Social, and Governance (ESG) Scores

Galmed Stock Institutional Investors

Note, although Galmed Pharmaceuticals' institutional investors appear to be way more sophisticated than retail investors, it remains unclear if professional active investment managers can reliably enhance risk-adjusted returns by an amount that exceeds fees and expenses.

Galmed Market Capitalization

The company currently falls under 'Nano-Cap' category with a current market capitalization of 3.36 M.

Galmed Profitablity

Management Efficiency

Galmed Pharmaceuticals has return on total asset (ROA) of (0.2198) % which means that it has lost $0.2198 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.3722) %, meaning that it created substantial loss on money invested by shareholders. Galmed Pharmaceuticals' management efficiency ratios could be used to measure how well Galmed Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities. The current year's Return On Capital Employed is expected to grow to 0.51, whereas Return On Tangible Assets are forecasted to decline to (0.39). At present, Galmed Pharmaceuticals' Non Current Assets Total are projected to increase significantly based on the last few years of reporting. The current year's Non Currrent Assets Other is expected to grow to about 856.1 K, whereas Total Current Assets are forecasted to decline to about 14.5 M.

Technical Drivers

As of the 25th of March, Galmed Pharmaceuticals retains the Market Risk Adjusted Performance of (0.46), standard deviation of 7.14, and Risk Adjusted Performance of (0.05). Galmed Pharmaceuticals technical analysis makes it possible for you to employ historical prices and volume momentum with the intention to determine a pattern that calculates the direction of the firm's future prices. Please check out Galmed Pharmaceuticals standard deviation, treynor ratio, as well as the relationship between the Treynor Ratio and potential upside to decide if Galmed Pharmaceuticals is priced fairly, providing market reflects its last-minute price of 2.03 per share. Please also validate Galmed Pharmaceuticals jensen alpha, which is currently at (0.47) to confirm the company can sustain itself at a future point.

Galmed Pharmaceuticals Price Movement Analysis

Galmed Pharmaceuticals Outstanding Bonds

Galmed Pharmaceuticals Predictive Daily Indicators

Galmed Pharmaceuticals Corporate Filings

Galmed Pharmaceuticals Forecast Models

Galmed Pharmaceuticals' time-series forecasting models are one of many Galmed Pharmaceuticals' stock analysis techniques aimed at predicting future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Galmed Pharmaceuticals' historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.

Stock analysis is the technique used by a trader or investor to examine and evaluate how Galmed Pharmaceuticals prices is reacting to, or reflecting on a current market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling Galmed shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas. a specific sector, or an individual Stock such as Galmed Pharmaceuticals. By using and applying Galmed Stock analysis, traders can create a robust methodology for identifying Galmed entry and exit points for their positions.

We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. Galmed analyst recommendations are determined by taking all analyst recommendations and averaging them as Strong Buy, Buy, Hold, Strong Sell or Sell. There is no one specific way to measure analysis performance other than comparing it to the past results via a very sophisticated attribution analysis. Galmed analyst consensus and target price projections should be used in combination with other traditional techniques such as stock price forecasting, technical analysis, earnings estimate, and various momentum models.

Galmed Pharmaceuticals stock analysis indicators help investors evaluate how Galmed Pharmaceuticals stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing and determine when trading Galmed Pharmaceuticals shares will generate the highest return on investment. By understating and applying Galmed Pharmaceuticals stock analysis, traders can identify Galmed Pharmaceuticals position entry and exit signals to maximize returns.

When running Galmed Pharmaceuticals' price analysis, check to measure Galmed Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Galmed Pharmaceuticals is operating at the current time. Most of Galmed Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Galmed Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Galmed Pharmaceuticals' price. Additionally, you may evaluate how the addition of Galmed Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.